Upgrade to SI Premium - Free Trial

ResMed (RMD) PT Raised to $238 at KeyBanc

April 26, 2024 2:22 AM
(Updated - April 26, 2024 8:17 AM EDT)

KeyBanc analyst Brett Fishbin raised the price target on ResMed (NYSE ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change